Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized

February 4th 2025

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

THIO Plus Cemiplimab Demonstrates Potential OS Benefit in Pretreated Advanced NSCLC

February 4th 2025

THIO plus cemiplimab generated a potential survival benefit in pretreated advanced non–small cell lung cancer.

Subcutaneous Amivantamab Nears EU Approval in Advanced EGFR+ NSCLC

February 4th 2025

The EMA’s CHMP has issued a positive opinion supporting the approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC

February 3rd 2025

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

CHMP Recommends Approval of Durvalumab for Limited-Stage Small Cell Lung Cancer

February 3rd 2025

The CHMP has recommended approval for durvalumab in limited-stage small cell lung cancer following platinum-based chemoradiation.

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer

February 2nd 2025

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Dr Levy on the Development and Clinical Use of ADCs in NSCLC

February 2nd 2025

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research

February 2nd 2025

Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC

February 2nd 2025

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC

February 2nd 2025

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy

February 2nd 2025

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer

February 1st 2025

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC

February 1st 2025

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC

February 1st 2025

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Dr Spira Details Future Directions for Amivantamab in NSCLC

January 30th 2025

Alexander I. Spira MD, PhD, FACP, FASCO, details the next steps for amivantamab in patients with EGFR–mutated locally advanced non–small cell lung cancer.

REZILIENT1 Study of Zipalertinib in Pretreated EGFR-Mutant NSCLC Meets ORR Primary End Point

January 29th 2025

The REZILIENT1 study of zipalertinib in pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations met its primary end point of ORR.

Tissue-Based NGS May Help Determine Relevant Gene Copy Number Gain Cutpoint for HER2/KRAS/MET in NSCLC

January 29th 2025

Findings from an oncogene overlap study in NSCLC support the potential clinical impact of high-level amplification of MET, HER2, and KRAS defined by NGS.

Watson Unpacks the Potential Clinical Impact of High-Level MET, HER2, and KRAS Amplifications in NSCLC

January 28th 2025

Alexander Watson, MD, DPhil, FRCPC, explains how the relationship between driver positivity and amplification status affects same-gene alteration enrichment.

Dr Horinouchi on Safety Data for Adjuvant Alectinib in ALK+ NSCLC

January 27th 2025

Hidehito Horinouchi, MD, PhD, discusses safety data for adjuvant alectinib vs chemotherapy in ALK-positive non–small cell lung cancer.

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC

January 23rd 2025

Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.